Wedbush Reiterates Outperform on Nuvation Bio, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating for Nuvation Bio (NYSE:NUVB) and maintained a price target of $5.
September 11, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating for Nuvation Bio and maintained a $5 price target, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $5 price target by a reputable analyst suggests positive sentiment and potential upside for Nuvation Bio's stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100